Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies
Giovedì 4 marzo 2021
circa 1 minuti di lettura
Journal and Affiliations:
Nature Medicine, 4 marzo 2021
Dora Pinto, Humabs BioMed, Bellinzona
Davide Corti, Humabs BioMed, Bellinzona
Tags:
SARS-CoV-2
vaccine
Authors:
Davide Corti
Dora Pinto